Novel radionuclide therapy combinations in prostate cancer

Prostate cancer remains the commonest cancer diagnosed in males and a leading cause of cancer-related death. Men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on chemotherapy and androgen receptor pathway inhibitors (ARPI) have limited treatment options, significan...

Descripción completa

Detalles Bibliográficos
Autores principales: Inderjeeth, Andrisha–Jade, Iravani, Amir, Subramaniam, Shalini, Conduit, Ciara, Sandhu, Shahneen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Advancing and Innovating in the Era of PSMA theranostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399256/
https://www.ncbi.nlm.nih.gov/pubmed/37547444
http://dx.doi.org/10.1177/17588359231187202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399256/
https://www.ncbi.nlm.nih.gov/pubmed/37547444
http://dx.doi.org/10.1177/17588359231187202

Ejemplares similares